Additional research in clinical studies is necessary to confirm whether NAC1 and LDHA can effectively serve as therapeutic targets, offering improved treatment options for patients with HBV-related liver cirrhosis and HCC. This evidence concerns the gene LDHA and hepatocellular carcinoma.